Clinical Trial Search

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Objective Responses Assessed by International Workshop Criteria (IWC) — 8; 5; 7 participants

Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants

Primary: Overall Response Rate — 0 percentage of participants

Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…

Primary: Progression Free Survival Probability at 12-month Post HCT — 0.80 probability

Primary: Overall Response (OR) Rate — 36 Participants

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1] — 0; 0; 3; 1 participants

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Objective Tumor Response — 0 participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants

Primary: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I) — 0; 1; 2; 0 Participants

Primary: Clinical Response Rate — 2; 0; 1; 1 participants

Primary: Progression-free Survival — 59 percent chance of PFS at 5 years

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Overall Response Rate (ORR) — 61 percentage of participants

Primary: Complete Response Rate at 20 Weeks — 45 percentage of participants

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Overall Response Rate — 53.8 percentage of participants

Primary: Overall Response Rate (ORR) and Disease Control Rate (DCR) Per Investigator at 6 Months (FAS) — 11.5; 22.7; 25.0; 30.8 percentage of participants

Primary: All Phase I-II Participants: Overall Response Rate (ORR) — 28 percentage of participants

Primary: Proportion of Patients Who Achieve a Confirmed Response — 0.0800; 0; 0 proportion of responders

Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants

Primary: Percentage of Participants With Response — 34.7 percentage of participants